Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
$1.50
$1.50
$0.64
$15.52
$13.16M3.2715,714 shsN/A
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
$7.99
+17.5%
$6.73
$6.65
$10.71
N/AN/A3,025 shs100 shs
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$74.02
+4.4%
$74.21
$53.12
$77.72
$12.35B0.58194,900 shs478,221 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
0.00%0.00%0.00%-5.52%+6.96%
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
0.00%0.00%+1.42%-6.21%-32.14%
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
+4.36%+4.37%+1.68%+6.44%+24.47%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
N/AN/AN/AN/AN/AN/AN/AN/A
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
N/AN/AN/AN/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
0.7143 of 5 stars
1.03.01.70.01.70.01.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
N/AN/AN/AN/A
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
N/AN/AN/AN/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
2.00
Hold$80.008.08% Upside

Current Analyst Ratings

Latest RDY, 9SP, LOQPF, and AHI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
1/29/2024
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$75.00 ➝ $80.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
$1.88M7.00N/AN/A$0.18 per share8.33
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
N/AN/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$2.99B4.13$4.36 per share16.97$16.87 per share4.39

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
-$8.64MN/A0.00N/AN/AN/AN/AN/A
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
N/AN/A0.00N/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$548M$3.7919.5317.971.7819.26%20.97%15.19%5/8/2024 (Estimated)

Latest RDY, 9SP, LOQPF, and AHI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
1/31/202412/31/2023
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$0.88$0.99+$0.11$0.99$827.81 million$867.00 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
N/AN/AN/AN/AN/A
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
N/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
$0.410.55%+13.13%10.82%4 Years

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
N/AN/AN/A
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
N/AN/AN/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
0.02
2.55
1.90

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
0.04%
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
N/A
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
14.02%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Advanced Health Intelligence Ltd stock logo
AHI
Advanced Health Intelligence
N/A8.77 million7.37 millionNot Optionable
accesso Technology Group plc stock logo
LOQPF
accesso Technology Group
711N/AN/ANot Optionable
Dr. Reddy's Laboratories Limited stock logo
RDY
Dr. Reddy's Laboratories
25,863166.88 million163.54 millionOptionable

RDY, 9SP, LOQPF, and AHI Headlines

SourceHeadline
Dr. Reddys Laboratories (NYSE:RDY) Shares Gap Up to $70.92Dr. Reddy's Laboratories (NYSE:RDY) Shares Gap Up to $70.92
marketbeat.com - April 25 at 4:49 PM
Dr. Reddy’s Issues Voluntary Nationwide Recall of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg Due to Sub-PotencyDr. Reddy’s Issues Voluntary Nationwide Recall of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg Due to Sub-Potency
usatoday.com - April 23 at 2:57 PM
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
zacks.com - April 18 at 12:16 PM
Dr. Reddys Laboratories Limited to Post FY2026 Earnings of $4.11 Per Share, Zacks Research Forecasts (NYSE:RDY)Dr. Reddy's Laboratories Limited to Post FY2026 Earnings of $4.11 Per Share, Zacks Research Forecasts (NYSE:RDY)
americanbankingnews.com - April 18 at 2:26 AM
Research Analysts Set Expectations for Dr. Reddys Laboratories Limiteds FY2026 Earnings (NYSE:RDY)Research Analysts Set Expectations for Dr. Reddy's Laboratories Limited's FY2026 Earnings (NYSE:RDY)
marketbeat.com - April 17 at 6:35 PM
Dr Reddys launches migraine management device in EuropeDr Reddy's launches migraine management device in Europe
devdiscourse.com - April 10 at 10:21 AM
Vanguard Group Inc. Grows Stake in Dr. Reddys Laboratories Limited (NYSE:RDY)Vanguard Group Inc. Grows Stake in Dr. Reddy's Laboratories Limited (NYSE:RDY)
marketbeat.com - April 7 at 4:10 AM
Dr. Reddys Laboratories (NYSE:RDY) Upgraded to Strong-Buy by StockNews.comDr. Reddy's Laboratories (NYSE:RDY) Upgraded to Strong-Buy by StockNews.com
marketbeat.com - April 5 at 11:10 PM
Assenagon Asset Management S.A. Has $13.65 Million Stock Holdings in Dr. Reddys Laboratories Limited (NYSE:RDY)Assenagon Asset Management S.A. Has $13.65 Million Stock Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)
marketbeat.com - March 29 at 5:16 AM
Pharmazz Inc. and Dr. Reddys Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in IndiaPharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India
finance.yahoo.com - March 22 at 10:02 AM
Heres Why Doctor Reddys (RDY) is a Strong Value StockHere's Why Doctor Reddy's (RDY) is a Strong Value Stock
zacks.com - March 20 at 10:41 AM
Dr. Reddys Laboratories launches Versavo® (bevacizumab) in the UKDr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK
businesswire.com - March 19 at 7:00 AM
Why Doctor Reddys (RDY) is a Top Value Stock for the Long-TermWhy Doctor Reddy's (RDY) is a Top Value Stock for the Long-Term
zacks.com - February 28 at 10:41 AM
Dr. Reddys Laboratories Limited - Depositary Receipt () (RDY) Price Target Increased by 5.17% to 71.72Dr. Reddy's Laboratories Limited - Depositary Receipt () (RDY) Price Target Increased by 5.17% to 71.72
msn.com - February 24 at 3:03 PM
Heres Why Doctor Reddys (RDY) is a Strong Momentum StockHere's Why Doctor Reddy's (RDY) is a Strong Momentum Stock
zacks.com - February 23 at 10:56 AM
Global Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising DemandGlobal Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising Demand
msn.com - February 22 at 8:07 PM
Novo to face Wegovy competition in India as local versions loom: ReutersNovo to face Wegovy competition in India as local versions loom: Reuters
msn.com - February 22 at 12:58 PM
Why Doctor Reddys (RDY) is a Top Growth Stock for the Long-TermWhy Doctor Reddy's (RDY) is a Top Growth Stock for the Long-Term
zacks.com - February 22 at 10:51 AM
RDY Jun 2024 60.000 callRDY Jun 2024 60.000 call
ca.finance.yahoo.com - February 6 at 8:54 PM
Dr. Reddys (RDY) Q3 Earnings and Revenues Surpass EstimatesDr. Reddy's (RDY) Q3 Earnings and Revenues Surpass Estimates
finance.yahoo.com - February 1 at 12:38 PM
Dr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2024 Earnings Call TranscriptDr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2024 Earnings Call Transcript
finance.yahoo.com - February 1 at 12:38 PM
Teva hits 52-week high on outlook, API divestmentTeva hits 52-week high on outlook, API divestment
msn.com - January 31 at 4:08 PM
UPDATE 1-Indian pharma firm Dr Reddys beats Q3 profit view on strong US, European businessesUPDATE 1-Indian pharma firm Dr Reddy's beats Q3 profit view on strong US, European businesses
finance.yahoo.com - January 31 at 4:08 PM
Dr. Reddy’s Q3 & 9M FY24 Financial ResultsDr. Reddy’s Q3 & 9M FY24 Financial Results
finance.yahoo.com - January 31 at 4:08 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Advanced Health Intelligence logo

Advanced Health Intelligence

NASDAQ:AHI
Advanced Health Intelligence Ltd. operates as a mobile application and technology development company in Australia and internationally. It offers biometric health assessments, a multi-step process that employs facial scanning, heart rate measurements, body composition analysis, and cardiovascular fitness tests that evaluates an individual's health. The company also provides FaceScan, process that estimates on heart rate, respiration rate, blood pressure, and other through facial scans; BodyScan, a smart body composition and dimensioning technology that enables user to check and assess body dimensions using a smartphone; and DermaScan, a dermatological scanner. It serves mobile health and telehealth, life and health insurance, wellness, and government sectors. The company was formerly known as Advanced Human Imaging Limited and changed its name to Advanced Health Intelligence Ltd. in December 2022. Advanced Health Intelligence Ltd. was incorporated in 2014 and is based in South Perth, Australia.
accesso Technology Group logo

accesso Technology Group

OTCMKTS:LOQPF
accesso Technology Group plc, together with its subsidiaries, develops technology solutions for the attractions and leisure industry in the United Kingdom, other European countries, Australia, the South Pacific, Asia, the United States, Canada, Mexico, and Central and South America. It operates through Ticketing and Distribution, and Guest Experience segments. The company offers ticketing solutions for theme parks, ski resorts, zoos and aquariums, cultural venues, live entertainment, water parks, fairs and festivals, performing arts, and tours and attractions. It also offers various solutions, such as accesso LoQueue, a virtual queuing solution; the experience engine, an experience management platform; and accesso Passport ticketing suite, which provides daily tickets, season pass, group tickets, meal vouchers, and other services. In addition, the company provides accesso Siriusware, a software solutions providing ticketing and admissions, memberships, reservations, resource scheduling, retail, food service, gift cards, kiosks, and ecommerce services; and accesso ShoWare, a ticketing solutions for box office, kiosk, online, mobile, call center, and social media sales. Further, it operates distribution platform which connects venues and distributors; and point of sale systems. The company was formerly known as Lo-Q plc and changed its name to accesso Technology Group plc in November 2013. accesso Technology Group plc was incorporated in 2000 and is based in Twyford, the United Kingdom.
Dr. Reddy

Dr. Reddy's Laboratories

NYSE:RDY
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.